Ivermectin — An Antiparasitic Drug With Well-Defined Medical Indications

Drug Overview

What Ivermectin Is, Where It Came From, and What It Treats

Ivermectin is a broad-spectrum antiparasitic drug belonging to the avermectin family — a class of compounds produced by the soil actinobacterium Streptomyces avermitilis, first isolated in 1973 from a soil sample collected near a golf course in Kawana, Japan. Merck researcher William Campbell and microbiologist Satoshi Ōmura of the Kitasato Institute jointly developed ivermectin from this organism's natural fermentation product. Their work ultimately earned them the 2015 Nobel Prize in Physiology or Medicine "for discoveries concerning a novel therapy against infections caused by roundworm parasites." The drug was approved for veterinary use in 1981 and for human parasitic infections in 1987.

How Ivermectin Works at the Cellular Level

Ivermectin's antiparasitic action is highly selective. The drug binds with very high affinity to glutamate-gated chloride ion channels found in the nerve and muscle cells of invertebrates — including nematodes (roundworms) and arthropods (mites, lice). Binding causes the channels to open permanently, allowing chloride ions to flood the cell. This hyperchlorination hyperpolarizes the nerve or muscle cell membrane, leading to paralysis and death of the parasite.

This mechanism is selective for invertebrates because vertebrate animals — including humans — have glutamate-gated chloride channels only in the central nervous system, where they are protected from circulating drugs by the blood-brain barrier. At standard therapeutic doses, ivermectin does not meaningfully cross the human blood-brain barrier, which explains its wide safety margin in human use. The exception is rare individuals with genetic mutations affecting P-glycoprotein (the efflux transporter responsible for excluding ivermectin from the CNS), in whom neurological toxicity can occur even at normal doses.

FDA-Approved Indications for Oral Ivermectin in Humans

Oral ivermectin tablets are FDA approved for two primary parasitic infections:

  • Intestinal strongyloidiasis (caused by Strongyloides stercoralis): a soil-transmitted roundworm infection that, unusually, can undergo auto-infection — the larvae re-infect the same host indefinitely without external reinfection, meaning the disease can persist for decades. Ivermectin is the first-line treatment with a cure rate above 95% in immunocompetent patients. The standard dose is 200 micrograms per kilogram of body weight, taken as a single oral dose on an empty stomach.
  • Onchocerciasis (caused by Onchocerca volvulus, also called river blindness): a filarial worm infection transmitted by blackflies (Simulium species) in parts of sub-Saharan Africa, Yemen, and Latin America. It is the second leading infectious cause of blindness worldwide. Ivermectin kills the microfilarial stage (the motile larvae released by adult worms), dramatically reducing skin and eye manifestations. The dose is 150 micrograms per kilogram, given as a single annual or semi-annual dose. It does not kill adult worms but suppresses the disease by eliminating the larvae responsible for tissue inflammation.

A topical formulation of ivermectin (1% cream, brand name Soolantra) is separately FDA approved for the inflammatory lesions of papulopustular rosacea, targeting Demodex folliculorum mites that contribute to the condition. Topical ivermectin lotion (Sklice) is also approved for head lice in patients aged six months and older.

Standard Dosing and Administration

For both oral indications, ivermectin is dosed by body weight, a critical point that distinguishes it from fixed-dose medications. Dose is calculated in micrograms per kilogram (mcg/kg):

  • Strongyloidiasis: 200 mcg/kg as a single dose taken on an empty stomach (at least 30 minutes before eating) with water. In immunocompromised patients, repeat dosing at two weeks is typically recommended due to higher auto-infection risk.
  • Onchocerciasis: 150 mcg/kg once, repeated at intervals of 6 to 12 months depending on endemicity and clinical protocol. This regimen is at the core of the Mectizan Donation Program (see sidebar).

There are no dose strengths differentiated by strength alone as with many pills — a single 3 mg tablet formulation is combined to reach the target weight-based dose. Common combinations include 3 mg, 6 mg, 9 mg, or 12 mg depending on the patient's weight in the therapeutic range.

The History of Ivermectin in Global Public Health

Beyond its clinical role, ivermectin's impact on global health is difficult to overstate. In 1987, Merck launched the Mectizan Donation Program, committing to donate ivermectin free of charge "for as long as needed" to all countries where onchocerciasis is endemic. Over three decades and more than four billion treatments later, the program has contributed to the near-elimination of river blindness in several countries and has provided a template for pharmaceutical-led tropical disease control. The WHO classified ivermectin as an essential medicine in 1987 specifically for this purpose.

Safety and Evidence

Side Effects and Safety Profile

Oral ivermectin at approved doses is generally well tolerated. The most important adverse reactions to be aware of include:

  • Mazzotti reaction: in patients with onchocerciasis, the mass killing of microfilariae after the first ivermectin dose triggers an immune response — fever, rash, facial edema, hypotension, and joint pain. This is not a drug toxicity reaction but a consequence of the parasite die-off and immune clearance. Severity depends on the initial microfilarial burden. Subsequent doses typically cause less pronounced reactions.
  • Gastrointestinal effects: nausea, diarrhea, vomiting, and abdominal pain occur in a minority of patients, more often with strongyloidiasis treatment.
  • Neurological effects: dizziness and somnolence are reported at low rates. Serious CNS toxicity (encephalopathy) is rare and almost exclusively documented in patients with extremely high microfilarial loads (loiasis co-infection) or in the rare P-glycoprotein-deficient population.

Ivermectin is not recommended in children weighing less than 15 kg, during pregnancy (limited safety data; risk-benefit must be assessed), or in breastfeeding mothers during the first week postpartum.

Drug Interactions and Contraindications

The most clinically significant interactions for ivermectin involve:

  • Warfarin: ivermectin has been reported to elevate INR (international normalized ratio) in patients taking warfarin. Close INR monitoring is advised around the time of ivermectin administration in anticoagulated patients.
  • CYP3A4 and P-glycoprotein inhibitors: drugs that inhibit these pathways (including certain antiretrovirals, azole antifungals, and some calcium channel blockers) can elevate ivermectin plasma levels and increase the risk of adverse effects.
  • Loiasis co-infection: patients in Loa loa-endemic regions of Central Africa with very high loiasis microfilaremia (above 30,000 mf/mL) face a specific risk of fatal encephalopathy if treated with ivermectin. Pre-treatment screening is part of mass drug administration protocols in co-endemic areas.

Off-Label Uses and What the Evidence Shows

Ivermectin gained significant public attention beginning in 2020 when some researchers and commentators proposed it as a treatment for COVID-19. Regulatory agencies including the US FDA, the WHO, and the European Medicines Agency reviewed the available evidence and issued guidance recommending against use outside of controlled clinical trials. A comprehensive Cochrane systematic review published in 2022, which pooled data from multiple randomized controlled trials, concluded that there was insufficient evidence to support ivermectin's use in COVID-19. The NIH COVID-19 Treatment Guidelines Panel similarly recommended against routine use.

This does not alter ivermectin's well-established and evidence-supported role as an antiparasitic agent for the conditions for which it carries regulatory approval. Its value in tropical infectious disease is not disputed and is supported by decades of clinical and epidemiological data at the population level.

About This Page

This article is for informational purposes and does not constitute medical advice. Clinical data, mechanism details, and dosing figures are drawn from the FDA prescribing information for ivermectin, WHO essential medicines guidance, the Cochrane Collaboration systematic review (2022), and peer-reviewed parasitology literature. Reviewed by a medical writing team, April 2026.